AJAX THERAPEUTICS
Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
AJAX THERAPEUTICS
Industry:
Biotechnology Life Science Medical
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.ajaxtherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
143 M USD
Technology used in webpage:
Euro CrUX Dataset CrUX Top 50m
Similar Organizations
Aerovate Therapeutics
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
Alphina Therapeutics
Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients.
MapLight Therapeutics
MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.
Anavo Therapeutics
Anavo Therapeutics provides therapeutic potential of human phosphatase biology.
Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Light Bio
Light Bio creates novel capabilities in bioluminescence by applying synthetic biology to the natural diversity of living light.
Alpenglow Biosciences
Alpenglow Biosciences is an end-to-end 3D pathology platform that aims to accelerate drug development and improve clinical diagnostics.
Neutrolis
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).
SaNOtize
SaNOtize is a biotech company using a platform technology for topical to treat upper respiratory and dermal infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
EcoR1 Capital
EcoR1 Capital investment in Series C - Ajax Therapeutics
Vivo Capital
Vivo Capital investment in Series C - Ajax Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Ajax Therapeutics
Goldman Sachs Asset Management
Goldman Sachs Asset Management investment in Series C - Ajax Therapeutics
Boxer Capital
Boxer Capital investment in Series C - Ajax Therapeutics
Inning One Ventures
Inning One Ventures investment in Series C - Ajax Therapeutics
Eli Lilly & Company Foundation
Eli Lilly & Company Foundation investment in Series C - Ajax Therapeutics
Point72 Ventures
Point72 Ventures investment in Series C - Ajax Therapeutics
Schrödinger
Schrödinger investment in Series C - Ajax Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Venture Round - Ajax Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-08-23 | Ajax Therapeutics Appoints Dr. David Steensma as Chief Medical Officer |
Official Site Inspections
http://www.ajaxtherapeutics.com Semrush global rank: 4.78 M Semrush visits lastest month: 1.96 K
- Host name: 30.40.74.34.bc.googleusercontent.com
- IP address: 34.74.40.30
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ajax Therapeutics"
Ajax Therapeutics - AJAX
About Ajax and our focus on hematologic cancers Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic cancers. However, many of these …See details»
Ajax Therapeutics - Crunchbase Company Profile
Organization. Ajax Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Ajax Therapeutics is a biotechnology company developing therapies to target …See details»
Ajax Therapeutics - LinkedIn
Ajax Therapeutics is pleased to announce that the first patient has been enrolled and dosed on clinical trial AJX-101, a first-in-human study of AJ1-11095 in patients with myelofibrosis who …See details»
Ajax Therapeutics Expands Management Team to Support …
Sep 29, 2021 “Craig has successfully built and managed Ajax’s distributed research organization, including the company’s collaboration with Schrödinger, from the Company’s …See details»
Ajax Therapeutics - PitchBook
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20240368157-A1: Forms and compositions of a jak2 inhibitor: Pending: 03-May-2023See details»
Ajax Therapeutics Announces FDA Clearance of IND Application …
May 13, 2024 – AJ1-11095 is the first Type II JAK2 Inhibitor to ever enter the clinic- – Phase 1 dose escalation study expected to begin in 2H 2024 – New York, NY and Cambridge, MA, …See details»
Ajax Therapeutics Expands Management Team to Support …
Sep 29, 2021 “Craig has successfully built and managed Ajax’s distributed research organization, including the company’s collaboration with Schrödinger, from the Company’s …See details»
Ajax Therapeutics - Craft
Ajax Therapeutics is a biotechnology company that develops novel therapies for treating haematologic malignancies. It aims to discover and develop new therapies with greater …See details»
Ajax Therapeutics Expands Management Team to Support
Sep 29, 2021 “Craig has successfully built and managed Ajax’s distributed research organization, including the company’s collaboration with Schrödinger, from the Company’s …See details»
Ajax Therapeutics Raises $40 Million Financing To Develop Novel …
Jun 1, 2021 Please find more information at www.ajaxtherapeutics.com. NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity …See details»
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
May 13, 2024 Ajax will now get a chance to prove those claims. On Monday, it closed a $95 million series C round and said the Food and Drug Administration has cleared the company to …See details»
Ajax Therapeutics Raises $40 Million Financing To Develop
Jun 1, 2021 NEW YORK--(BUSINESS WIRE)-- Ajax Therapeutics, Inc., a biotechnology company applying computational chemistry and structure-based technologies to develop novel …See details»
Ajax Therapeutics Raises $40 Million Financing To Develop Novel …
Jun 1, 2021 Financing led by EcoR1 Capital with additional new investor, Boxer Capital Strategic collaboration with co-founder, Schrödinger, Inc., to develop pipeline of selectively targeted …See details»
JAK Attack: Ajax Takes Aim at Myelofibrosis - genengnews.com
May 19, 2024 Last year Jakafi generated $2.594 billion in U.S. net product revenues (up 8% year-over-year) and another $1.72 billion in rest-of-world net sales (up 10%).See details»
Ajax Therapeutics Appoints Dr. David Steensma as Chief Medical …
NEW YORK, August 23, 2023--Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK …See details»
Ajax Therapeutics Appoints Dr. David Steensma - Business Wire
Aug 23, 2023 Please find more information at www.ajaxtherapeutics.com. NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity …See details»
Ajax Therapeutics Raises $95 Million Series C Financing To …
May 13, 2024 Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic – Financing led by Goldman Sachs …See details»
Ajax Therapeutics Announces Oral and Poster Presentations on …
Nov 3, 2022 Please find more information at www.ajaxtherapeutics.com. NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity …See details»
Ajax Therapeutics Appoints Eric S. Fischer, PhD, to Scientific …
May 24, 2023 Please find more information at www.ajaxtherapeutics.com. NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity …See details»
Ajax Therapeutics Announces First Patient Dosed in Phase 1 …
Oct 30, 2024 – AJ1-11095 is the first Type II JAK2 Inhibitor to enter the clinic – – Preclinically, AJ1-11095 has demonstrated superior efficacy to Type I JAK2 inhibitors, such as ruxolitinib, …See details»